The CHLOR-DETOX study is a single-centre, double-blind, prospective, interventional, controlled, exploratory pilot study on subjects environmentally exposed to the organochlorine pesticide (kepone or chlordecone, CLD) in the French Caribbean (Martinique island). To our best knowledge, it is the first clinical trial in such subjects evaluating the potential effect of oral probiotic intake (Limosilactobacillus reuteri) on the reduction of CLD plasma levels (chlordeconemia) and fecal excretion, thus concurring to the reduction of CLD toxicity in study subjects.
Male or female, 18 years of age or older
Seen in clinical toxicology consultation at the CHU of Martinique during the study period
With an initial chlordeconemia > 1μg/L on a test less than 1 month old at the time of study inclusion
Affiliated to a social security scheme
History of cancer
Recent infections less than 6 months old
Known digestive diseases: chronic diarrhoea, ulcerative colitis, Crohn's disease, pancreatitis
Digestive procedures less than 6 months old.
Parallel
Limosilactobacillus reuteri
Dietary supplementThe BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour. \*Colony forming Unit
Placebo
Other interventionThe placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
Chlordeconemia
Chlordeconemia measured by a gas chromatography/mass spectrometry (GC/MS) technique expressed in μg/L (analytical detection limit LDD of 0.05 μg/L - quantification limit LDQ of 0.1 μg/L) The relative change in chlordeconemia between T0 and T6 months will be compared between the group of patients treated with the BioGaia® Gastrus probiotic and the group of patients treated with placebo. This relative variation will be calculated as the ratio of the difference in chlordeconemia T0 -T6mois to the initial chlordeconemia at T0.
Chlordeconemia
Chlordeconemia measured by a gas chromatography/mass spectrometry (GC/MS) technique expressed in μg/L (analytical detection limit LDD of 0.05 μg/L - quantification limit LDQ of 0.1 μg/L The relative change in chlordeconemia between T0 and T3months will be compared between the BioGaia® Gastrus probiotic treated group and the placebo treated group. This relative variation will be calculated as the ratio of the difference in chlordeconemia T0 -T3months to the initial chlordeconemia at T0.
Variation of chlordeconemia
The relative variation of chlordeconemia from T0 to T6 months in each group of patients (probiotic group, placebo group) will be described. The plasma half-life values of CLD, expressed in months, will be determined for each group.
concentration of CLD in the stool
The concentration of CLD in the stool at 3 months (T3 months) and 6 months (T6 months) will be measured using the same method described in the primary outcome (GC/MS technique). The relative changes in stool CLD concentration between T0 and T3mois and T0 and T6mois will be compared between the BioGaia® Gastrus probiotic treated group and the placebo treated group.
Variation of chlordecone concentration in stool
\- The relative change in stool CLD concentration from T0 to T6months within each patient group (probiotic group, placebo group) will be described
Click on the lead sponsor to view all of their trials.
University Hospital Center of Martinique
Lead sponsor
BioGaia AB
Collaborator
University Hospital, Limoges
Collaborator
Regional Health Agency, Martinique
Collaborator
Biological Resource Centre, Martinique
Collaborator
Reims University hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
